IBEX Limited (IBEX)
Valuation Overview•Is IBEX Limited Overvalued or Undervalued?
Commands a premium valuation multiple over its peers, likely pricing in superior execution.
Moderate quality score of 62/100, reflecting stable operating margins and manageable leverage.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Verdict: Solid fundamental quality, though profitability presents a headwind.
Wall Street is cautious, forecasting potential downside alongside robust expected earnings growth. This outlook is strongly supported by highly attractive capital returns, driven predominantly by aggressive share repurchases.
Returns capital exclusively via buybacks — no active dividend
IBEX demonstrates adequate business quality with stable profitability. This is supported by a highly conservative balance sheet featuring strong liquidity and pristine Altman Z safety.
The company exhibits steady, low-single-digit revenue growth paired with highly explosive earnings growth (27.1% EPS 3Y CAGR). Operating efficiency remains adequate with margins around 9.2%.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $164.4M | +9.8% | +4.2% | +6.6% | — | |
| EBITDA | $21.3M | — | +18.1% | — | — | |
| Net Income | $13.3M | +9.5% | +19.8% | — | — | |
| EPS (Diluted) | $0.89 | +28.3% | +27.1% | +39.9% | — | |
| Free Cash Flow | $6.6M | +0.9% | +24.7% | -10.5% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 21.3% | 29.7% | 27.5% | 26.3% |
| Operating Margin | 9.2% | 7.9% | 6.4% | 3.5% |
| Net Margin | 7.5% | 6.4% | 5.3% | 2.0% |
| FCF Margin | 5.2% | 4.9% | 3.3% | 2.0% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.85 | $0.91 | +6.4% | ||
| Q1'26 | $0.79 | $0.87 | +10.8% | ||
| Q4'25 | $0.81 | $0.90 | +11.1% | ||
| Q3'25 | $0.73 | $0.87 | +18.4% | ||
| Q2'25 | $0.73 | $0.82 | +12.3% | ||
| Q1'25 | $0.49 | $0.59 | +20.4% | ||
| Q4'24 | $0.48 | $0.52 | +8.3% | ||
| Q3'24 | $0.53 | $0.58 | +9.4% |
Total return is +6.9% (1Y), lagging the benchmark by -18.1%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -16.8% | -26.1% | — |
| 1Y | +6.9% | -18.1% | — |
| 3YCAGR | +12.6% | -6.5% | — |
| 5YCAGR | +9.6% | -1.3% | — |
| 10YCAGR | +7.0% | -6.6% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about IBEX Limited (IBEX) valuation, health, and returns.
Based on peer relative multiples, IBEX Limited appears Expensive versus peers compared to industry peers.
IBEX Limited has multiple valuation anchors: Peer Relative Fair Value: $14.12 | Wall Street Analyst Target: $24.00 (implying -20.6% upside). A convergence of these signals offers higher conviction.
IBEX Limited displays good financial health with a composite quality score of 62/100, supported by a Altman Z-Score of 4.8 (safe zone), Piotroski F-Score of 7/9, Return on Invested Capital (ROIC) of 19.5%.
IBEX Limited returns capital via buybacks instead of dividends, carrying a 19.2% buyback yield and reducing outstanding shares by -13.9% in the last 12 months.
IBEX Limited's current growth trajectory is Accelerating. The company achieved +9.8% 1Y revenue growth and +28.3% 1Y EPS growth, compared to its 3Y revenue CAGR of +4.2%.
Wall Street consensus is Hold based on 6 analysts, beating EPS expectations in 83% of recent quarters with a 9-quarter streak. The consensus price target represents a -20.6% change from current levels.
Investment risks for IBEX Limited include: -37.1% 1-year max drawdown. Volatility risk is characterized by a beta of 0.91x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.